Clinical Trials

81 enrolled

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04560127 2025-07-10

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

20 enrolled

EndocrineHead & Neck

Radioactive Iodine-refractory Differentiated Thyroid Cancer

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

75 enrolled

Locally Advanced Thyroid Gland Carcinoma

NCT05069857 2023-11-22

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Phase 2 Recruiting

46 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03267121 2023-10-17

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

58 enrolled

Nasopharyngeal Carcinoma

NCT03180476 2023-04-14

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

21 enrolled

Nasopharyngeal Neoplasms

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Nasopharyngeal Carcinoma

NCT04350190 2023-01-13

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

25 enrolled

Nasopharyngeal Carcinoma

NCT02731352 2022-01-20

Study of Apatinib in Patients With Differentiated Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT02874651 2022-01-11

ADVANCE

Phase 2 Terminated

25 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT04440917 2021-02-02

IMplus

32 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04612894 2020-11-03

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

31 enrolled

Thyroid Neoplasms

NCT04547088 2020-09-14

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

27 enrolled

Nasopharyngeal Carcinoma

NCT04548271 2020-09-14

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

25 enrolled

Nasopharyngeal Carcinoma

NCT04180007 2019-11-27

APT-01

10 enrolled

Neoplasm Metastasis, Thyroid Diseases

NCT03096184 2018-10-09

A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03612219 2018-08-02

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

240 enrolled

Nasopharyngeal Carcinoma

NCT03539172 2018-05-30

RASS

61 enrolled

Head & NeckSarcoma

Head and Neck Neoplasms, Sarcoma, Neoplasms, Connective and Soft Tissue

NCT03130270 2018-05-16

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

29 enrolled

Nasopharyngeal Carcinoma

NCT03424291 2018-02-06

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

60 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT03300765 2017-10-03

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT03213587 2017-07-11

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

51 enrolled

Nasopharyngeal Carcinoma

NCT02989259 2016-12-13

Apatinib for Advanced Non-squamous Head and Neck Cancer

30 enrolled

Head and Neck Neoplasms

NCT02943252 2016-10-24

The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer

30 enrolled